Notes
Understanding TreatmentOptions in
Cutaneous Lymphoma
38
58. Valencak J,RadererM.Treatment of primary cutaneousB-cell lymphomas:
an overview.
Eur JClinMedOncol
. 2009;1(1):1-8.
59. NeelisKJ, Schimmel EC,VermeerMH, SenffNJ,WillemzeR,Noordijk
EM.Low-dose palliative radiotherapy for cutaneous B- andT-cell
lymphomas.
Int JRadiatOncol Biol Phys
. 2009;74(1):154-158.
60. PenateY,Hernandez-MachinB,Perez-MendezLI, et al. Intralesional
rituximab in the treatment of indolent primary cutaneousB-cell
lymphomas: an epidemiological observationalmulticentre study.The
SpanishWorkingGroup onCutaneousLymphoma.
Br JDermatol
.
2012;167(1):174-179.
61. GrangeF,MaubecE,BagotM, et al.Treatment of cutaneousB-cell
lymphoma, leg type,with age-adapted combinations of chemotherapies and
rituximab.
ArchDermatol
. 2009;145(3):329-330.
62. FenotM,QuereuxG,BrocardA,Renaut JJ,DrenoB.Rituximab for
primary cutaneous diffuse largeB-cell lymphoma-leg type.
Eur JDermatol
.
2010;20(6):753-757.
63. MoralesAV,Advani R,Horwitz SM, et al. Indolent primary cutaneous
B-cell lymphoma: experience using systemic rituximab.
JAmAcadDermatol
.
2008;59(6):953-957.
64. Valencak J,Weihsengruber F,RappersbergerK, et al.Rituximab
monotherapy for primary cutaneous B-cell lymphoma: response and follow-
up in 16 patients.
AnnOncol
. 2009;20(2):326-330.
65. Maza S,GellrichS,AssafC, et al.Yttrium-90 ibritumomab tiuxetan
radioimmunotherapy inprimary cutaneous B-cell lymphomas: first results
of a prospective,monocentre study.
LeukLymphoma
. 2008;49(9):1702-1709.
Perf.
Perf.
Notes
__________________________________________________________________________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________________________________________________________________
Understanding TreatmentOptions in
Cutaneous Lymphoma
